- Home
- OXBR vs ALLR Comparison
OXBR vs ALLR Comparison
Compare OXBR & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXBR
- ALLR
- Stock Information
- Founded
- OXBR 2013
- ALLR 2004
- Country
- OXBR Cayman Islands
- ALLR United States
- Employees
- OXBR N/A
- ALLR N/A
- Industry
- OXBR Property-Casualty Insurers
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- OXBR Finance
- ALLR Health Care
- Exchange
- OXBR Nasdaq
- ALLR Nasdaq
- Market Cap
- OXBR 16.9M
- ALLR 15.8M
- IPO Year
- OXBR 2014
- ALLR N/A
- Fundamental
- Price
- OXBR $2.20
- ALLR $1.50
- Analyst Decision
- OXBR Strong Buy
- ALLR Strong Buy
- Analyst Count
- OXBR 1
- ALLR 1
- Target Price
- OXBR $5.00
- ALLR $9.00
- AVG Volume (30 Days)
- OXBR 48.2K
- ALLR 20.3M
- Earning Date
- OXBR 08-14-2025
- ALLR 08-15-2025
- Dividend Yield
- OXBR N/A
- ALLR N/A
- EPS Growth
- OXBR N/A
- ALLR N/A
- EPS
- OXBR N/A
- ALLR N/A
- Revenue
- OXBR $1,983,000.00
- ALLR N/A
- Revenue This Year
- OXBR $497.99
- ALLR N/A
- Revenue Next Year
- OXBR $42.14
- ALLR N/A
- P/E Ratio
- OXBR N/A
- ALLR N/A
- Revenue Growth
- OXBR N/A
- ALLR N/A
- 52 Week Low
- OXBR $1.27
- ALLR $0.61
- 52 Week High
- OXBR $5.81
- ALLR $5.94
- Technical
- Relative Strength Index (RSI)
- OXBR 65.07
- ALLR 78.25
- Support Level
- OXBR $1.55
- ALLR $1.36
- Resistance Level
- OXBR $2.48
- ALLR $2.35
- Average True Range (ATR)
- OXBR 0.18
- ALLR 0.14
- MACD
- OXBR 0.06
- ALLR 0.07
- Stochastic Oscillator
- OXBR 70.94
- ALLR 48.34
About OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.